Lexicon Pharmaceuticals, Inc. (LXRX)
NASDAQ · Healthcare
Lexicon Pharmaceuticals, Inc. EBITDA 2009–2025
Lexicon Pharmaceuticals, Inc. annual/quarterly ebitda history and growth rate from 2009 to 2026. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Lexicon Pharmaceuticals, Inc. ebitda for the quarter ending March 31, 2026 was -886000, a 96.53% decrease year-over-year.
- Lexicon Pharmaceuticals, Inc. ebitda for the twelve months ending March 31, 2026 was -102.6 M, a 24.38% decrease year-over-year.
- Lexicon Pharmaceuticals, Inc. annual ebitda for 2025 was -48.3 M, a 75.44% decrease from 2024.
- Lexicon Pharmaceuticals, Inc. annual ebitda for 2024 was -196.6 M, a 14.83% increase from 2023.
- Lexicon Pharmaceuticals, Inc. annual ebitda for 2023 was -171.2 M, a 70.63% increase from 2022.
- Lexicon Pharmaceuticals, Inc. annual ebitda for 2022 was -100.3 M.
EBITDA
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Lexicon Pharmaceuticals, Inc. EBITDA — FAQ
Lexicon Pharmaceuticals, Inc. (LXRX) ebitda over the last 17 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see LXRX's ebitda history?
The chart and table above show Lexicon Pharmaceuticals, Inc.'s ebitda by year and by quarter, including the growth rate.